Boiron France / Boiron France

boiron.fr

Boiron is a family-owned and independent pharmaceutical company. We are specialized in the manufacture of homeopathic medicines of very high quality for a century. Present in more than 50 countries, with 3,708 employees, we develop with rigor and passion our project for health. Boiron is an independent, family-run pharmaceutical laboratory.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

LTS COMPLETES ITS ENTRY INTO LARGE MOLECULE DRUG DELIVERY WITH THE ACQUISITION OF THE SORREL WEARABLE INJECTION DEVICE BUSINESS

PRNewswire | June 09, 2023

news image

LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"), Oral Thin Films ("OTF") and Micro Array Patches ("MAP") has completed its acquisition of the Sorrel wearable injection device business ("Sorrel") with headquarters in Netanya, Israel, from Eitan Medical Ltd ("Eitan Medical"). Terms of the transacti...

Read More

Pharmacy Market

SONIVIE RECEIVES IDE APPROVAL FROM FDA FOR ITS PILOT STUDY TO TREAT HYPERTENSION WITH ITS RENAL ARTERY DENERVATION TIVUS™ TECHNOLOGY

SoniVie | June 20, 2022

news image

SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System to treat a variety of hypertensive disorders, announced that on May 5th 2022 the U.S. Food and Drug Administration granted IDE approval for its "REDUCED1" Pilot study to treat Resistant Hypertension Patients with Renal Artery Denervation using TIVUS™, its innovative Ultra-Sound Ablation System. Resistant hypertension is defined as blood pressure higher than...

Read More

PHARMACY MARKET

HALOZYME ANNOUNCES POSITIVE CLINICAL DATA OF ITS HIGH-VOLUME AUTO-INJECTOR DEMONSTRATING SUCCESSFUL RAPID SUBCUTANEOUS DRUG DELIVERY

PR Newswire | October 19, 2023

news image

Halozyme Therapeutics, Inc. announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds. In the study, the biologic was delivered with Halozyme's proprietary high-volume auto-injector (HVAI) in healthy volunteers. The injecti...

Read More

Pharmacy Market

CORRECTING AND REPLACING SENJU PHARMACEUTICAL AND NOVALIQ ENTER INTO LICENSE AGREEMENT FOR NOV03 FOR THE TREATMENT OF DRY EYE DISEASE IN JAPAN

Businesswire | June 15, 2023

news image

Senju Pharmaceutical Co., Ltd., a researched-based Japanese pharmaceutical company focusing the field of ophthalmology, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free technology, are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for si...

Read More
news image

Pharmacy Market

LTS COMPLETES ITS ENTRY INTO LARGE MOLECULE DRUG DELIVERY WITH THE ACQUISITION OF THE SORREL WEARABLE INJECTION DEVICE BUSINESS

PRNewswire | June 09, 2023

LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"), Oral Thin Films ("OTF") and Micro Array Patches ("MAP") has completed its acquisition of the Sorrel wearable injection device business ("Sorrel") with headquarters in Netanya, Israel, from Eitan Medical Ltd ("Eitan Medical"). Terms of the transacti...

Read More
news image

Pharmacy Market

SONIVIE RECEIVES IDE APPROVAL FROM FDA FOR ITS PILOT STUDY TO TREAT HYPERTENSION WITH ITS RENAL ARTERY DENERVATION TIVUS™ TECHNOLOGY

SoniVie | June 20, 2022

SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System to treat a variety of hypertensive disorders, announced that on May 5th 2022 the U.S. Food and Drug Administration granted IDE approval for its "REDUCED1" Pilot study to treat Resistant Hypertension Patients with Renal Artery Denervation using TIVUS™, its innovative Ultra-Sound Ablation System. Resistant hypertension is defined as blood pressure higher than...

Read More
news image

PHARMACY MARKET

HALOZYME ANNOUNCES POSITIVE CLINICAL DATA OF ITS HIGH-VOLUME AUTO-INJECTOR DEMONSTRATING SUCCESSFUL RAPID SUBCUTANEOUS DRUG DELIVERY

PR Newswire | October 19, 2023

Halozyme Therapeutics, Inc. announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds. In the study, the biologic was delivered with Halozyme's proprietary high-volume auto-injector (HVAI) in healthy volunteers. The injecti...

Read More
news image

Pharmacy Market

CORRECTING AND REPLACING SENJU PHARMACEUTICAL AND NOVALIQ ENTER INTO LICENSE AGREEMENT FOR NOV03 FOR THE TREATMENT OF DRY EYE DISEASE IN JAPAN

Businesswire | June 15, 2023

Senju Pharmaceutical Co., Ltd., a researched-based Japanese pharmaceutical company focusing the field of ophthalmology, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free technology, are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for si...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us